Medicilon Congratulates AI-Driven Biotech Insilico Medicine on Its HKEX Debut in Hong Kong’s Largest Biotech IPO of 2025

On December 30, Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence, successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 3696.HK). The offering raised HK$2.277 billion, making it the largest biotech IPO in Hong Kong in 2025 and the first AI-driven biotech company to list under Listing […]